Literature DB >> 12960696

Peripheral blood T-cell clonality in mycosis fungoides and nonlymphoma controls.

J Marcus Muche1, Wolfram Sterry, Sylke Gellrich, Berthold Rzany, Heike Audring, Ansgar Lukowsky.   

Abstract

In mycosis fungoides (MF), T-cell clonality is reported in about 90% of skin and 40% of blood samples. However, identity of blood and cutaneous T-cell clone and prognostic relevance of blood T-cell clonality remain controversial. By PCR/fluorescence fragment analysis with estimation of clonal fragment lengths and relative peak heights, we objectively identified T-cell clonality unrelated to malignant lymphoproliferation in healthy donors (5/38), autoimmune dermatoses (3/8), and nonlymphoma skin cancer (9/39). This T-cell expansion of undetermined significance (TEXUS) was also found in 8/64 MF patients. Dissemination of neoplastic cells into blood, as identified by identical clonal fragment lengths in blood and skin, was detected in 23/64 MF patients. When monitoring for progression at TNM stage for a mean of 45.7 months, univariate analysis identified age of >60 years and detection of a related blood T-cell clone to be of prognostic relevance, whereas detection of TEXUS, sex, TNM stage at initial diagnosis, and detection of a cutaneous T-cell clone were irrelevant. Although multivariate analysis was not possible, further stratification clearly indicated an age of >60 years to be the predominating prognostic factor. In conclusion, investigation of T-cell clonality in skin and blood samples at the initial diagnosis cannot predict the clinical course of MF and the occurrence of TEXUS should be considered when assessing blood T-cell clonality.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12960696     DOI: 10.1097/00019606-200309000-00005

Source DB:  PubMed          Journal:  Diagn Mol Pathol        ISSN: 1052-9551


  6 in total

1.  BIOMED-2 multiplex immunoglobulin/T-cell receptor polymerase chain reaction protocols can reliably replace Southern blot analysis in routine clonality diagnostics.

Authors:  Yorick Sandberg; Ellen J van Gastel-Mol; Brenda Verhaaf; King H Lam; Jacques J M van Dongen; Anton W Langerak
Journal:  J Mol Diagn       Date:  2005-10       Impact factor: 5.568

Review 2.  Immunopathogenesis and therapy of cutaneous T cell lymphoma.

Authors:  Ellen J Kim; Stephen Hess; Stephen K Richardson; Sara Newton; Louise C Showe; Bernice M Benoit; Ravi Ubriani; Carmela C Vittorio; Jacqueline M Junkins-Hopkins; Maria Wysocka; Alain H Rook
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

3.  CD30 expression and proliferative fraction in nontransformed mycosis fungoides.

Authors:  James T Edinger; Beth Z Clark; Brian E Pucevich; Larisa J Geskin; Steven H Swerdlow
Journal:  Am J Surg Pathol       Date:  2009-12       Impact factor: 6.394

4.  Clinical, histopathological, immunophenotypic and molecular analysis of 60 patients with cutaneous T-cell infiltrates with follow up of indeterminate cases to identify T-cell lymphoma.

Authors:  Nóra Eros; Zsuzsánna Károlyi; Márta Marschalkó; Sarolta Kárpáti; András Matolcsy
Journal:  Pathol Oncol Res       Date:  2008-04-08       Impact factor: 3.201

5.  Diagnostic Value of Genotypic Analysis in Primary Cutaneous Lymphomas using Standardized BIOMED-2 Polymerase Chain Reaction Protocols: Experience in Daily Clinical Practice.

Authors:  Daniel López Aventín; Fernando Gallardo; Luis Colomo; Ester Moragón; María Carmen Vela; Xavier Duran Jordà; Beatriz Bellosillo; Ramon M Pujol
Journal:  Acta Derm Venereol       Date:  2021-05-19       Impact factor: 3.875

6.  Expression of human endogenous retrovirus-w including syncytin-1 in cutaneous T-cell lymphoma.

Authors:  Pilvi Maliniemi; Michelle Vincendeau; Jens Mayer; Oliver Frank; Sonja Hahtola; Leena Karenko; Emilia Carlsson; Francois Mallet; Wolfgang Seifarth; Christine Leib-Mösch; Annamari Ranki
Journal:  PLoS One       Date:  2013-10-01       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.